Das28 calculator
Author: l | 2025-04-24
Download DAS28 Calculator latest version for iOS free. DAS28 Calculator latest update: J
Das28 calculator app - denisonlandscaping.com
Of patients who achieved an ACR20 response, changes in Health Assessment Questionnaire – Disability Index (HAQ-DI), and rates of Disease Activity Score DAS28-4(ESR) less than 2.6.Study RA-II (NCT00856544) was a 12-month trial in which 792 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to a nonbiologic DMARD received XELJANZ 5 or 10 mg twice daily or placebo added to background DMARD treatment (excluding potent immunosuppressive treatments such as azathioprine or cyclosporine). At the Month 3 visit, nonresponding patients were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. At the end of Month 6, all placebo patients were advanced to their second predetermined treatment in a blinded fashion. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, changes in HAQ-DI at Month 3, and rates of DAS28-4(ESR) less than 2.6 at Month 6.Study RA-III (NCT00853385) was a 12-month trial in 717 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to MTX. Patients received XELJANZ 5 or 10 mg twice daily, adalimumab 40 mg subcutaneously every other week, or placebo added to background MTX. Placebo patients were advanced as in Study II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6.Study RA-IV (NCT00847613) was a 2-year trial with a planned analysis at 1 year in which 797 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to MTX received XELJANZ 5 or 10 mg twice daily or placebo added to background MTX. Placebo patients were advanced as in Study II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, mean change from baseline in van der Heijde-modified total Sharp Score (mTSS) at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6.Study RA-V (NCT00960440) was a 6-month trial in which 399 patients with moderate to severe active rheumatoid arthritis who had For placebo treatment is not available beyond 3 months in Studies I and V due to placebo advancement. ACR20Month 326%59%27%55%24%41%Month 6NA¶69%25%50%NA51%ACR50Month 312%31%8%29%8%26%Month 6NA42%9%32%NA37%ACR70Month 36%15%3%11%2%14%Month 6NA22%1%14%NA16%In Study RA-IV, a greater proportion of patients treated with XELJANZ 5 mg twice daily plus MTX achieved a low level of disease activity as measured by a DAS28-4(ESR) less than 2.6 at 6 months compared to those treated with MTX alone (Table 10).Table 10: Proportion of Patients with DAS28-4(ESR) Less Than 2.6 with Number of Residual Active JointsStudy IVDAS28-4(ESR) Less Than 2.6Placebo + MTXXELJANZ 5 mg Twice Daily + MTX160321Proportion of responders at Month 6 (n)1% (2)6% (19)Of responders, proportion with 0 active joints (n)50% (1)42% (8)Of responders, proportion with 1 active joint (n)05% (1)Of responders, proportion with 2 active joints (n)032% (6)Of responders, proportion with 3 or more active joints (n)50% (1)21% (4)The results of the components of the ACR response criteria for Study RA-IV are shown in Table 11. Similar results were observed for XELJANZ in Studies RA-I, II, III, V, and VI.Table 11: Components of ACR Response at Month 3Study IVXELJANZ5 mgTwice Daily + MTXPlacebo + MTXN=321N=160Component (mean) *BaselineMonth 3*BaselineMonth 3**Data shown is mean (Standard Deviation) at Month 3. †Visual analog scale: 0 = best, 100 = worst.‡Health Assessment Questionnaire Disability Index: 0 = best, 3 = worst; 20 questions; categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.Number of tender joints(0–68)24(14)13(14)23(13)18(14)Number of swollen joints(0–66)14(8)6(8)14(9)10(9)Pain†58(23)34(23)55(24)47(24)Patient global assessment†58(24)35(23)54(23)47(24)Disability index(HAQ-DI)‡1.41(0.68)0.99(0.65)1.32(0.67)1.19(0.68)Physician global assessment†59(16)30(19)56(18)43(22)CRP (mg/L)15.3(19.0)7.1(19.1)13.7(14.9)14.6(18.7)The percent of ACR20 responders by visit for Study RA-IV is shown in Figure 4. Similar responses were observed for XELJANZ in Studies RA-I, II, III, V, and VI.Figure 4: Percentage of ACR20 Responders by Visit for Study RA-IV Radiographic ResponseTwo studies were conducted to evaluate the effect of XELJANZ on structural joint damage. In Study RA-IV and Study RA-VI, progression of structural joint damage was assessed radiographically and expressed as change from baseline in mTSS and its components, the erosion score and joint space narrowing score, at Months 6 and 12. The proportion of patients with no radiographic progression (mTSS change less than or equal to 0) wasDAS DAS28 calculators - DAS-score
An inadequate response to at least one approved TNF blocking biologic agent received XELJANZ 5 or 10 mg twice daily or placebo added to background MTX. At the Month 3 visit, all patients randomized to placebo treatment were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. The primary endpoints at Month 3 were the proportion of patients who achieved an ACR20 response, HAQ-DI, and DAS28-4(ESR) less than 2.6.Study RA-VI (NCT01039688) was a 2-year monotherapy trial with a planned analysis at 1 year in which 952 MTX-naïve patients with moderate to severe active rheumatoid arthritis received XELJANZ 5 or 10 mg twice daily or MTX dose-titrated over 8 weeks to 20 mg weekly. The primary endpoints were mean change from baseline in van der Heijde-modified Total Sharp Score (mTSS) at Month 6 and the proportion of patients who achieved an ACR70 response at Month 6.Clinical ResponseThe percentages of XELJANZ-treated patients achieving ACR20, ACR50, and ACR70 responses in Studies RA-I, IV, and V are shown in Table 9. Similar results were observed with Studies RA-II and III. In trials RA-I through V, patients treated with 5 mg twice daily XELJANZ had higher ACR20, ACR50, and ACR70 response rates versus placebo, with or without background DMARD treatment, at Month 3 and Month 6. Higher ACR20 response rates were observed within 2 weeks compared to placebo. In the 12-month trials, ACR response rates in XELJANZ-treated patients were consistent at 6 and 12 months.Table 9: Proportion of Patients with an ACR ResponsePercent of PatientsMonotherapy in Nonbiologic or Biologic DMARD Inadequate Responders*MTX Inadequate Responders†TNF Blocker Inadequate Responders‡Study IStudy IVStudy VN§PBOXELJANZ5 mg Twice DailyPBO + MTXXELJANZ5 mg Twice Daily + MTXPBO + MTXXELJANZ 5 mg Twice Daily + MTX122243160321132133*Inadequate response to at least one DMARD (biologic or nonbiologic) due to lack of efficacy or toxicity.†Inadequate response to MTX defined as the presence of sufficient residual disease activity to meet the entry criteria.‡Inadequate response to a least one TNF blocker due to lack of efficacy and/or intolerance.§N is number of randomized and treated patients.¶NA Not applicable, as data. Download DAS28 Calculator latest version for iOS free. DAS28 Calculator latest update: J How is DAS28-ESR calculated? DAS28-ESR is calculated using a specific formula involving the tender joint count, swollen joint count, and the ESR. What does DAS28-ESR measure? DAS28-ESR measures disease activity in patients with rheumatoid arthritis. How often should DAS28-ESR be calculated?DAS28 CRP For Rheumatoid Arthritis Calculator
Providing a systematic way to account for the reduction in value over time. This is a common method used in accounting to allocate the cost of assets and determine their book value. All calculators 401k retirement calculator ADR calculator APY calculator Acid test ratio calculator Amortization calculator Asset finance calculator Auto loan calculator Basis point calculator Break even calculator Business loan calculator Business savings calculator Business valuation calculator California sales tax calculator Car finance calculator Car finance settlement calculator Cash flow calculator Commercial mortgage calculator Commercial real estate calculator Compound annual growth rate calculator Compound interest calculator Cost of equity calculator Currency converter Debt service coverage ratio calculator Development finance calculator Dividend calculator EBITDA calculator Employee retention credit calculator Florida sales tax calculator Franchise loan calculator Home equity line of credit payoff calculator Inflation calculator Internal rate of return calculator Invoice factoring calculator Invoice finance calculator Lease calculator Line of credit calculator Loss ratio calculator Marginal cost calculator Merchant cash advance (MCA) calculator Missouri sales tax calculator Mortgage overpayment calculator Net profit margin calculator New Jersey sales tax calculator Ohio sales tax calculator Operating margin calculator PayPal fee calculator Percentage calculator Pre money valuation calculator Price elasticity of demand calculator Price per square foot calculator Price to earnings calculator R&D tax credit calculator Rate of return calculator Receivables turnover calculator Refinance calculator Rent vs. buy calculator Return on capital employed calculator Return on investment calculator Revenue calculator SBA loan calculator Sales tax calculator Short term business loan calculator Weighted average For phone and tablet, this application includes the complete package of financial calculators by Bishinew Inc: Finance and Investment Calculators * TVM Calculator * TVM Advanced Calculator * Currency Converter * Compound Interest Calculator * Compound Interest Advanced Calculator * APR Calculator * Mutual Fund Fee Calculator * Return On Investment (ROI) Calculator * Rule of 72 Calculator * Effective Rate Calculator * IRR NPV Calculator * MIRR Calculator * Tax Equivalent Yield Calculator * US Inflation Calculator * Hourly to Salary Calculator * Salary Increase Calculator * US Paycheck Tax Calculator * Net Distribution Tax Calculator * Investment Income Calculator * Health Savings Account Calculator Loan/Mortgage Calculators * Loan Calculator * Loan Comparison Calculator * Loan Refinance Calculator * Loan Analysis Calculator * Loan Analysis Advanced Calculator * Commercial Loan Calculator * Loan Term Calculator * Fixed Principal Loan Calculator * Home Affordability Loan Calculator * Rent vs Buy Loan Calculator * Mortgage Tax Saving Loan Calculator * Discount Points Loan Calculator * Adjustable Rate Loan Calculator * Fixed vs Adjustable Rate Loan Calculator * Bi-weekly Payment Loan Calculator * Interest Only Loan Calculator * Rule of 78 Loan Calculator Retirement Calculators * Retirement/401k Contribution Calculator * Retirement Calculator * Retirement Savings Analysis * Retirement Income Analysis * Traditional IRA vs Roth IRA - Retirement * Required Minimum Distribution - Retirement * Social Security Estimator - Retirement * Asset Allocation Calculator - Retirement * Start Early and Save Regularly - Retirement * Set Goal for Retirement - Retirement * Max Out 401k/IRA Savings - Retirement * Invest Wisely - Retirement * How Much Money Will I Need? - Retirement * How Long Does My Money Last? - Retirement * How Much Should I Withdraw? - Retirement * Inflation Matters - Retirement * 401k Save the Max Calculator * College Savings Calculator Bond Calculators * Bond Calculator * Bond Yield to Call (YTC) Calculator * Bond Yield to Maturity (YTM) Calculator * Bond Duration Calculator Stock Calculators * Stock Return Calculator * Stock Constant Growth Calculator * Stock Non-constant Growth Calculator * CAPM Calculator * Expected Return Calculator * Holding Period Return Calculator * Weighted Average Cost of Capital Calculator * Pivot Point Calculator * Fibonacci Calculator * Black-Scholes Option Calculator Credit Card Calculators * Credit Card Payoff Calculator * Credit Card Minimum Calculator Auto Loan and Lease Calculators * Auto Loan Calculator * Auto Lease Calculator Business Accounting Calculators * Depreciation Calculator * Break Even Point Calculator * Margin and Markup Calculator * Investment Income Calculator * US Health Savings Account Calculator * Certificate of Deposit (CD) Calculator * Recurring Deposit (RD) Calculator * Financial Ratios General Calculators * Regular Calculator * Tip Calculator * Discount and Tax Calculator * Percentage Calculator * Unit Price Compare Calculator * Unit Conversion * Date Calculator * Fuel Calculator * BMI Calculator * Tax/VAT/GST CalculatorUser can send the calculation results to others via Email. Financial Professionals can email the quote to their clients.The app allows you to edit and prioritize the listDAS28-CRP Calculator - DAS-score
Solutions > Chemistry Calculator > Topic Pre AlgebraAlgebraPre CalculusCalculusFunctionsLinear AlgebraTrigonometryStatisticsPhysicsChemistryChemical ReactionsChemical PropertiesFinanceEconomicsConversions Full pad x^2 x^{\msquare} \log_{\msquare} \sqrt{\square} \nthroot[\msquare]{\square} \le \ge \frac{\msquare}{\msquare} \cdot \div x^{\circ} \pi \left(\square\right)^{'} \frac{d}{dx} \frac{\partial}{\partial x} \int \int_{\msquare}^{\msquare} \lim \sum \infty \theta (f\:\circ\:g) f(x) Steps Graph Related Examples Generated by AI AI explanations are generated using OpenAI technology. AI generated content may present inaccurate or offensive content that does not represent Symbolab's view. Verify your Answer Subscribe to verify your answer Subscribe Save to Notebook! Sign in to save notes Sign in Verify Save Show Steps Hide Steps Number Line Related Chemistry Examples CH_{4}+O_{2}\Rightarrow CO_{2}+H_{2}O SO_{2}+H_{2}\Rightarrow S+2H_{2}O P_{4}+O_{2}\Rightarrow P_{2}O_{5} Description Calculate chemical reactions and chemical properties step-by-step chemistry-calculator en Related Symbolab blog posts Practice Makes Perfect Learning math takes practice, lots of practice. Just like running, it takes practice and dedication. If you want... Popular topics scientific calculator inverse calculator simplify calculator distance calculator fractions calculator interval notation calculator cross product calculator probability calculator derivative calculator series calculator ratios calculator statistics calculator integral calculator inverse laplace transform calculator rounding calculator gcf calculator algebra calculator tangent line calculator trigonometry calculator log calculator standard deviation calculator linear equation calculator antiderivative calculator laplace transform calculator quadratic equation calculator domain calculator decimals calculator limit calculator equation solver definite integral calculator matrix inverse calculator matrix calculator system of equations calculator calculus calculator slope calculator long division calculator factors calculator polynomial calculator square root calculator implicit differentiation calculator word problem solver differential equation calculator average calculator synthetic division calculator Chat with Symbo AI may present inaccurate or offensive content that does not represent Symbolab's views. Do not enter any personal information Enter a problem Cooking Calculators Cooking Measurement Converter Cooking Ingredient Converter Cake Pan Converter More calculators Fitness Calculators BMI Calculator Calorie Calculator BMR Calculator More calculators Save to Notebook! Sign in Notebook View Full NotebookDAS28 ESR For Rheumatoid Arthritis Calculator
Solutions > Topic Pre AlgebraAlgebraPre CalculusCalculusFunctionsLinear AlgebraTrigonometryStatisticsPhysicsChemistryFinanceEconomicsConversions Full pad x^2 x^{\msquare} \log_{\msquare} \sqrt{\square} \nthroot[\msquare]{\square} \le \ge \frac{\msquare}{\msquare} \cdot \div x^{\circ} \pi \left(\square\right)^{'} \frac{d}{dx} \frac{\partial}{\partial x} \int \int_{\msquare}^{\msquare} \lim \sum \infty \theta (f\:\circ\:g) f(x) Steps Graph Related Examples Generated by AI AI explanations are generated using OpenAI technology. AI generated content may present inaccurate or offensive content that does not represent Symbolab's view. Verify your Answer Subscribe to verify your answer Subscribe Save to Notebook! Sign in to save notes Sign in Verify Save Show Steps Hide Steps Number Line Related Examples x^{2}-x-6=0 -x+3\gt 2x+1 line\:(1,\:2),\:(3,\:1) f(x)=x^3 prove\:\tan^2(x)-\sin^2(x)=\tan^2(x)\sin^2(x) \frac{d}{dx}(\frac{3x+9}{2-x}) (\sin^2(\theta))' \sin(120) \lim _{x\to 0}(x\ln (x)) \int e^x\cos (x)dx \int_{0}^{\pi}\sin(x)dx \sum_{n=0}^{\infty}\frac{3}{2^n} Description Solve problems from Pre Algebra to Calculus step-by-step step-by-step 64^{\frac{1}{2}} en Related Symbolab blog posts Practice Makes Perfect Learning math takes practice, lots of practice. Just like running, it takes practice and dedication. If you want... Popular topics median calculator dot product calculator arc length calculator maclaurin series calculator z score calculator critical point calculator inequalities calculator range calculator determinant calculator second derivative calculator lcm calculator partial derivative calculator complete the square calculator distributive property calculator mixed fractions calculator Time Calculator gradient calculator triple integrals calculator partial fractions calculator indefinite integral calculator solve for x calculator double integral solver vector calculator Date Calculator vertex calculator binomial expansion calculator decimal to fraction calculator difference quotient calculator eigenvalue calculator piecewise functions calculator radius of convergence calculator roots calculator exponential function calculator interval of convergence calculator fractions divide calculator inflection point calculator expand calculator variance calculator fractions multiply calculator fourier series calculator foil calculator modulo calculator series convergence calculator linear algebra calculator Chat with Symbo AI may present inaccurate or offensive content that does not represent Symbolab's views. Do not enter any personal information Enter a problem Cooking Calculators Cooking Measurement Converter Cooking Ingredient Converter Cake Pan Converter More calculators Fitness Calculators BMI Calculator Calorie Calculator BMR Calculator More calculators Save to Notebook! Sign in Notebook View Full Notebook. Download DAS28 Calculator latest version for iOS free. DAS28 Calculator latest update: JHow to calculate the DAS28 - DAS-score
Solutions > Topic Pre AlgebraAlgebraPre CalculusCalculusFunctionsLinear AlgebraTrigonometryStatisticsPhysicsChemistryFinanceEconomicsConversions Full pad x^2 x^{\msquare} \log_{\msquare} \sqrt{\square} \nthroot[\msquare]{\square} \le \ge \frac{\msquare}{\msquare} \cdot \div x^{\circ} \pi \left(\square\right)^{'} \frac{d}{dx} \frac{\partial}{\partial x} \int \int_{\msquare}^{\msquare} \lim \sum \infty \theta (f\:\circ\:g) f(x) Steps Graph Related Examples Generated by AI AI explanations are generated using OpenAI technology. AI generated content may present inaccurate or offensive content that does not represent Symbolab's view. Verify your Answer Subscribe to verify your answer Subscribe Save to Notebook! Sign in to save notes Sign in Verify Save Show Steps Hide Steps Number Line Related Examples x^{2}-x-6=0 -x+3\gt 2x+1 line\:(1,\:2),\:(3,\:1) f(x)=x^3 prove\:\tan^2(x)-\sin^2(x)=\tan^2(x)\sin^2(x) \frac{d}{dx}(\frac{3x+9}{2-x}) (\sin^2(\theta))' \sin(120) \lim _{x\to 0}(x\ln (x)) \int e^x\cos (x)dx \int_{0}^{\pi}\sin(x)dx \sum_{n=0}^{\infty}\frac{3}{2^n} Description Solve problems from Pre Algebra to Calculus step-by-step step-by-step \frac{12}{5}-7 en Related Symbolab blog posts Practice Makes Perfect Learning math takes practice, lots of practice. Just like running, it takes practice and dedication. If you want... Popular topics median calculator dot product calculator arc length calculator maclaurin series calculator z score calculator critical point calculator inequalities calculator range calculator determinant calculator second derivative calculator lcm calculator partial derivative calculator complete the square calculator distributive property calculator mixed fractions calculator Time Calculator gradient calculator triple integrals calculator partial fractions calculator indefinite integral calculator solve for x calculator double integral solver vector calculator Date Calculator vertex calculator binomial expansion calculator decimal to fraction calculator difference quotient calculator eigenvalue calculator piecewise functions calculator radius of convergence calculator roots calculator exponential function calculator interval of convergence calculator fractions divide calculator inflection point calculator expand calculator variance calculator fractions multiply calculator fourier series calculator foil calculator modulo calculator series convergence calculator linear algebra calculator Chat with Symbo AI may present inaccurate or offensive content that does not represent Symbolab's views. Do not enter any personal information Enter a problem Cooking Calculators Cooking Measurement Converter Cooking Ingredient Converter Cake Pan Converter More calculators Fitness Calculators BMI Calculator Calorie Calculator BMR Calculator More calculators Save to Notebook! Sign in Notebook View Full NotebookComments
Of patients who achieved an ACR20 response, changes in Health Assessment Questionnaire – Disability Index (HAQ-DI), and rates of Disease Activity Score DAS28-4(ESR) less than 2.6.Study RA-II (NCT00856544) was a 12-month trial in which 792 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to a nonbiologic DMARD received XELJANZ 5 or 10 mg twice daily or placebo added to background DMARD treatment (excluding potent immunosuppressive treatments such as azathioprine or cyclosporine). At the Month 3 visit, nonresponding patients were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. At the end of Month 6, all placebo patients were advanced to their second predetermined treatment in a blinded fashion. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, changes in HAQ-DI at Month 3, and rates of DAS28-4(ESR) less than 2.6 at Month 6.Study RA-III (NCT00853385) was a 12-month trial in 717 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to MTX. Patients received XELJANZ 5 or 10 mg twice daily, adalimumab 40 mg subcutaneously every other week, or placebo added to background MTX. Placebo patients were advanced as in Study II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6.Study RA-IV (NCT00847613) was a 2-year trial with a planned analysis at 1 year in which 797 patients with moderate to severe active rheumatoid arthritis who had an inadequate response to MTX received XELJANZ 5 or 10 mg twice daily or placebo added to background MTX. Placebo patients were advanced as in Study II. The primary endpoints were the proportion of patients who achieved an ACR20 response at Month 6, mean change from baseline in van der Heijde-modified total Sharp Score (mTSS) at Month 6, HAQ-DI at Month 3, and DAS28-4(ESR) less than 2.6 at Month 6.Study RA-V (NCT00960440) was a 6-month trial in which 399 patients with moderate to severe active rheumatoid arthritis who had
2025-04-10For placebo treatment is not available beyond 3 months in Studies I and V due to placebo advancement. ACR20Month 326%59%27%55%24%41%Month 6NA¶69%25%50%NA51%ACR50Month 312%31%8%29%8%26%Month 6NA42%9%32%NA37%ACR70Month 36%15%3%11%2%14%Month 6NA22%1%14%NA16%In Study RA-IV, a greater proportion of patients treated with XELJANZ 5 mg twice daily plus MTX achieved a low level of disease activity as measured by a DAS28-4(ESR) less than 2.6 at 6 months compared to those treated with MTX alone (Table 10).Table 10: Proportion of Patients with DAS28-4(ESR) Less Than 2.6 with Number of Residual Active JointsStudy IVDAS28-4(ESR) Less Than 2.6Placebo + MTXXELJANZ 5 mg Twice Daily + MTX160321Proportion of responders at Month 6 (n)1% (2)6% (19)Of responders, proportion with 0 active joints (n)50% (1)42% (8)Of responders, proportion with 1 active joint (n)05% (1)Of responders, proportion with 2 active joints (n)032% (6)Of responders, proportion with 3 or more active joints (n)50% (1)21% (4)The results of the components of the ACR response criteria for Study RA-IV are shown in Table 11. Similar results were observed for XELJANZ in Studies RA-I, II, III, V, and VI.Table 11: Components of ACR Response at Month 3Study IVXELJANZ5 mgTwice Daily + MTXPlacebo + MTXN=321N=160Component (mean) *BaselineMonth 3*BaselineMonth 3**Data shown is mean (Standard Deviation) at Month 3. †Visual analog scale: 0 = best, 100 = worst.‡Health Assessment Questionnaire Disability Index: 0 = best, 3 = worst; 20 questions; categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.Number of tender joints(0–68)24(14)13(14)23(13)18(14)Number of swollen joints(0–66)14(8)6(8)14(9)10(9)Pain†58(23)34(23)55(24)47(24)Patient global assessment†58(24)35(23)54(23)47(24)Disability index(HAQ-DI)‡1.41(0.68)0.99(0.65)1.32(0.67)1.19(0.68)Physician global assessment†59(16)30(19)56(18)43(22)CRP (mg/L)15.3(19.0)7.1(19.1)13.7(14.9)14.6(18.7)The percent of ACR20 responders by visit for Study RA-IV is shown in Figure 4. Similar responses were observed for XELJANZ in Studies RA-I, II, III, V, and VI.Figure 4: Percentage of ACR20 Responders by Visit for Study RA-IV Radiographic ResponseTwo studies were conducted to evaluate the effect of XELJANZ on structural joint damage. In Study RA-IV and Study RA-VI, progression of structural joint damage was assessed radiographically and expressed as change from baseline in mTSS and its components, the erosion score and joint space narrowing score, at Months 6 and 12. The proportion of patients with no radiographic progression (mTSS change less than or equal to 0) was
2025-04-24An inadequate response to at least one approved TNF blocking biologic agent received XELJANZ 5 or 10 mg twice daily or placebo added to background MTX. At the Month 3 visit, all patients randomized to placebo treatment were advanced in a blinded fashion to a second predetermined treatment of XELJANZ 5 or 10 mg twice daily. The primary endpoints at Month 3 were the proportion of patients who achieved an ACR20 response, HAQ-DI, and DAS28-4(ESR) less than 2.6.Study RA-VI (NCT01039688) was a 2-year monotherapy trial with a planned analysis at 1 year in which 952 MTX-naïve patients with moderate to severe active rheumatoid arthritis received XELJANZ 5 or 10 mg twice daily or MTX dose-titrated over 8 weeks to 20 mg weekly. The primary endpoints were mean change from baseline in van der Heijde-modified Total Sharp Score (mTSS) at Month 6 and the proportion of patients who achieved an ACR70 response at Month 6.Clinical ResponseThe percentages of XELJANZ-treated patients achieving ACR20, ACR50, and ACR70 responses in Studies RA-I, IV, and V are shown in Table 9. Similar results were observed with Studies RA-II and III. In trials RA-I through V, patients treated with 5 mg twice daily XELJANZ had higher ACR20, ACR50, and ACR70 response rates versus placebo, with or without background DMARD treatment, at Month 3 and Month 6. Higher ACR20 response rates were observed within 2 weeks compared to placebo. In the 12-month trials, ACR response rates in XELJANZ-treated patients were consistent at 6 and 12 months.Table 9: Proportion of Patients with an ACR ResponsePercent of PatientsMonotherapy in Nonbiologic or Biologic DMARD Inadequate Responders*MTX Inadequate Responders†TNF Blocker Inadequate Responders‡Study IStudy IVStudy VN§PBOXELJANZ5 mg Twice DailyPBO + MTXXELJANZ5 mg Twice Daily + MTXPBO + MTXXELJANZ 5 mg Twice Daily + MTX122243160321132133*Inadequate response to at least one DMARD (biologic or nonbiologic) due to lack of efficacy or toxicity.†Inadequate response to MTX defined as the presence of sufficient residual disease activity to meet the entry criteria.‡Inadequate response to a least one TNF blocker due to lack of efficacy and/or intolerance.§N is number of randomized and treated patients.¶NA Not applicable, as data
2025-03-27